Guner Abdullah Emre, Surmeli Aral, Kural Kemal, Yilmaz Habip, Kocayigit Erdogan, Sahin Esra, Alkan Perihan, Kazezoglu Cemal, Zelyurt Serdal, Memisoglu Kemal, Maral Isil
Istanbul Health Directorate, Public Health Services, Istanbul, Turkey.
Medical Rescue Association of Turkey, Istanbul, Turkey.
North Clin Istanb. 2021 Mar 22;8(2):119-123. doi: 10.14744/nci.2021.60420. eCollection 2021.
The objective of this study was to understand the observational relationship between adoption of favipiravir into the national COVID-19 treatment protocol and intensive care unit (ICU) admission rates in Istanbul due to COVID-19.
Data were harvested from the "Public Health Management System-HSYS," which collate centrally the records of all known cases of COVID-19. The total number of cases, numbers admitted to ICU, and number undergoing intubation were compared between 2 time periods: 11 of March, the date on which the first case in Turkey was confirmed, to 30 of March; and March 30, to 10 of April, 5 days after Favipiravir was introduced into the treatment algorithm when, the records were examined.
The percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%. These differences were both statistically significant.
The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation.
本研究的目的是了解将法匹拉韦纳入国家新冠肺炎治疗方案与伊斯坦布尔因新冠肺炎导致的重症监护病房（ICU）收治率之间的观察性关联。
数据取自“公共卫生管理系统-HSYS”，该系统集中整理了所有已知新冠肺炎病例的记录。在两个时间段内比较了病例总数、入住ICU的人数和接受插管的人数：从土耳其首例病例确诊的3月11日至3月30日；以及从3月30日至4月10日，即法匹拉韦被纳入治疗方案后的第5天，此时对记录进行了检查。
需要入住ICU的患者百分比从24%降至12%，同时接受插管的百分比从77%降至66%。这些差异均具有统计学意义。
在国家新冠肺炎治疗方案中添加法匹拉韦可能解释了ICU收治率和插管率的快速下降。
